title: Lamivudine therapy of WHV-infected woodchucks.
abstract: Hepatitis B viruses establish a chronic, productive, and noncytopathic infection of hepatocytes. Viral products are produced by transcription from multiple copies (5-50) of covalently closed circular (ccc) viral DNA. This cccDNA does not replicate, but can be replaced by DNA precursors that are synthesized in the cytoplasm. The present study was carried out to determine if long-term treatment with an inhibitor of viral DNA synthesis would lead to loss of virus products, including cccDNA, from the liver of woodchucks chronically infected with woodchuck hepatitis virus. Viral DNA synthesis was inhibited with the nucleoside analog, lamivudine (2'-deoxy-3'-thiacytidine). Lamivudine treatment produced a slow but progressive decline in viral titers in serum, to about 0.3% or less of the initial level. However, even after maintenance of drug therapy for 3-12 months, > 95% of the hepatocytes in most animals were still infected. Significant declines in the percentage of infected hepatocytes and of intrahepatic cccDNA levels were observed in only three woodchucks, two in the group receiving lamivudine and one in the placebo control group. Moreover, virus titers eventually rose in woodchucks receiving lamivudine, suggesting that drug-resistant viruses began to spread through the liver starting at least as early as 9-12 months of treatment. Three types of mutation that may be associated with drug resistance were found at this time, in a region upstream of the YMDD motif in the active site of the viral reverse transcriptase. The YMDD motif itself remained unchanged. Not unexpectedly, the lamivudine therapy did not have a impact on development of liver cancer.
authors.affiliation: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. ws_mason@fccc.edu
authors.forename: W S
authors.initials: WS
authors.lastname: Mason
authors.forename: J
authors.initials: J
authors.lastname: Cullen
authors.forename: G
authors.initials: G
authors.lastname: Moraleda
authors.forename: J
authors.initials: J
authors.lastname: Saputelli
authors.forename: C E
authors.initials: CE
authors.lastname: Aldrich
authors.forename: D S
authors.initials: DS
authors.lastname: Miller
authors.forename: B
authors.initials: B
authors.lastname: Tennant
authors.forename: L
authors.initials: L
authors.lastname: Frick
authors.forename: D
authors.initials: D
authors.lastname: Averett
authors.forename: L D
authors.initials: LD
authors.lastname: Condreay
authors.forename: A R
authors.initials: AR
authors.lastname: Jilbert
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000187:drug effects / Q000235:genetics; D006515:Hepatitis B virus / Q000302:isolation & purification* / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D019259:Lamivudine / Q000627:therapeutic use*; D008392:Marmota; D008969:Molecular Sequence Data; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
chemical_list: D004279:DNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine